Risk Reduction In mRNA Therapeutic Development: Meet The Panel
Source: Roche CustomBiotech
In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, we meet our guests, Christian Dohmen, Senior Director of Formulation & Aerosol Research at Ethris, and Patrick Baumhof, SVP of Technology at CureVac. Christian and Patrick review the key drivers behind the flurry of activity in mRNA Therapeutic Development and begin to address the rate-limiting risks to mRNA therapeutic development.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Roche CustomBiotech
This website uses cookies to ensure you get the best experience on our website. Learn more